Normal-Weight Fatty Liver Disease Linked to Higher Risk of Death, Heart Problems, Cancer, and Less Use of GLP-1 Medication

Long-term outcomes and incretin-based therapy use were compared between normal-BMI MASLD and overweight/obesity-associated MASLD.

• Normal-BMI MASLD occurs in individuals who are not overweight or obese.
• The burden and management of normal-BMI MASLD are not well understood.
• Differences in long-term outcomes may exist between normal-BMI MASLD and overweight/obesity-associated MASLD.
• Incretin-based therapy usage varies across different racial and ethnic groups in relation to MASLD.

Simplified